Category: Recent news

SPI2 Study Evaluating High Dose Pharmaceutical Grade Biotin is on Track to Report Top-Line Results in Q1 2020 Paris, France, December 12, 2019 MedDay Pharmaceuticals, a pioneering biotechnology company focusing…Continue readingMedDay Reports Last Patient Study Visit in Second Phase 3 Clinical Trial with MD1003®, an Important Milestone Towards Completion of the SPI2 Study in Progressive Multiple Sclerosis

Paris, France, March 10, 2020 MedDay Pharmaceuticals announced today that the second pivotal Phase III trial (SPI2) of its investigational product MD1003 has not met its primary and secondary endpoints.…Continue readingMedDay Reports Top-Line Data from Phase III Trial “SPI2” for Treatment of Progressive Forms of Multiple Sclerosis

Paris, France, May 20, 2020 MedDay Pharmaceuticals announced today that results from the pivotal Phase III study “SPI2” evaluating its investigational product MD1003 will be presented at the upcoming Virtual…Continue readingPresentation of “SPI2” Phase III Results at the EAN Virtual Congress 2020

Top-line results of the SPI2 trial expected by Q1 2020 NDA (USA) and MAA (Europe) filings expected by H2 2020 Paris, France, November 9, 2018 MedDay Pharmaceuticals, an international pioneering…Continue readingMedDay Pharmaceuticals Announces Full Patient Enrollment for MD1003 Phase III Clinical Trial (SPI2) in Progressive Multiple Sclerosis

Paris, France, April 27 2015 MedDay, a biotechnology company focused on the treatment of nervous system disorders, today announces it will webcast its post-AAN Clinical Trials Plenary Session, on Tuesday…Continue readingMedDay to webcast results of its pivotal Phase III study of MD1003 in patients with Progressive Multiple Sclerosis